#Pre-Filled Auto Injectors Market Analysis
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Tumblr has 4 main sources of revenue.
Link
Pre-filled auto-injectors are defined as unit dose medication for parenteral administration. Pre-filled auto-injectors are intended for self-administration by patients.
#Pre-Filled Auto Injectors Market Share#Pre-Filled Auto Injectors Market Analysis#Pre-Filled Auto Injectors Market Trends#Pre-Filled Auto Injectors Market Growth
0 notes
Text
Injectable Drug Delivery Market Size, Share, Industry Growth, Trend, Business Opportunities, Challenges, Drivers and Restraint Research Report by 2030
The report studies the historical data of the Injectable Drug Delivery Market and offers valuable information about the key segments and sub-segments, revenue generation, demand and supply scenario, trends, and other vital aspects. The report offers an accurate forecast estimation of the Injectable Drug Delivery Market based on the recent technological and research advancements.
The global injectable drug delivery market size reached USD 15.13 Billion in 2021 and is expected to register a revenue CAGR of 9.1% during the forecast period, according to latest analysis by Emergen Research. Injectable drug delivery market revenue growth is owing to a rising trend of pre-filled syringes along with technological developments. Initially, medication was only available in the form of tablets, pills, or capsules; however, medicines are now given via more technologically advanced and intelligent methods. These systems are meant to deliver medications to a specific location, allowing them to be more localized than would be possible through the circulatory system.
Advanced injectable devices are preferred by patients who take medications daily over standard injection devices. As a result, growing demand for effective and convenient drug delivery systems gives manufacturers a potential growth opportunity to develop advanced, user-friendly, and effective drug delivery devices. Increasing frequency of chronic illnesses and other life-threatening disorders highlights the need for new and effective medications across a wide range of treatment areas.
Get a sample of the report @ https://www.emergenresearch.com/industry-report/injectable-drug-delivery-market
Regional Analysis - The research report is an investigative study providing a conclusive view of the Injectable Drug Delivery business sphere by an in-depth segmentation of the market into key applications, types, and regions. These segments are analysed on the basis of present, emerging, and future trends. The regional segmentation provides current and forecast demand estimation for the Injectable Drug Delivery industry in key regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Some major companies in global market report include Vetter Pharma, Akorn Operating Company LLC, Catalent, Inc., Pfizer Inc., Gerresheimer AG, Elcam Medical, Schott, SHL Medical AG, Becton, Dickinson & Company, and West Pharmaceutical Services, Inc.
Key questions addressed in the report:
What are the key factors driving the global Injectable Drug Delivery market?
Who are the key manufacturers in this market space?
Who are the distributors, traders and dealers of this market?
What are the market opportunities and risks affecting the performance of the vendors in the global Injectable Drug Delivery market?
What are the sales and revenue estimations for the top manufacturers in this market over the projected timeline?
Emergen Research has segmented global injectable drug delivery market on the basis of device type, product type, end-use, and region:
Device Type Outlook (Revenue, USD Billion; 2019-2030)
Product Type Outlook (Revenue, USD Billion; 2019-2030)
End-use Outlook (Revenue, USD Billion; 2019-2030)
Conventional Injectables
Pre-Filled Syringes
Auto-Injectors
Pen-Injectors
Freeze-Dried Products
Injectable Sterile Products
Hospitals
Homecare Settings
Clinics
Others
Key point summary of the report:
The report offers a comprehensive overview of the market size, share, and growth rate in the forecast duration.
It provides details about current scenario, historical data, giving an accurate market forecast for the coming years.
The study categorizes the market on the basis of product types, applications, end users, market value and volume, business verticals, and 5 major regions.
It also offers regional market analysis and forecast for prominent geographies in the sector viz., North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Take a Look at our Related Reports:
Industry 4.0 Market
https://www.google.it.ao/url?q=https://www.emergenresearch.com/industry-report/industry-4-market
Big Data Analytics in Manufacturing Market
https://www.google.it.ao/url?q=https://www.emergenresearch.com/industry-report/big-data-analytics-in-manufacturing-market
Next-Generation Biomanufacturing Market
https://www.google.it.ao/url?q=https://www.emergenresearch.com/industry-report/next-generation-biomanufacturing-market
Deep Learning Chip
https://www.google.it.ao/url?q=https://www.emergenresearch.com/industry-report/deep-learning-chip-market
Vehicle-to-Everything (V2X)
https://www.google.it.ao/url?q=https://www.emergenresearch.com/industry-report/vehicle-to-everything-market
Big Data Analytics in BFSI
https://www.google.it.ao/url?q=https://www.emergenresearch.com/industry-report/big-data-analytics-in-bfsi-market
Structured Cabling Market
https://www.google.it.ao/url?q=https://www.emergenresearch.com/industry-report/structured-cabling-market
Deep Learning System
https://www.google.it.ao/url?q=https://www.emergenresearch.com/industry-report/deep-learning-system-market
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: [email protected]
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
0 notes
Text
Prefilled Syringes Market To Surge Beyond $22.5 Billion By 2025
The global prefilled syringes market size is expected to reach a value of USD 22.5 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 11.2% during the forecast years. Growing usage of prefilled syringes and technological advancements in auto-injectors are the key factors driving the market. Prefilled syringes are rapidly replacing traditional syringe-vial combinations due to advantages offered by them, such as increased patient safety and convenience for healthcare practitioners in dose preparation and delivery.
These syringes enable easy management of chronic diseases, such as diabetes and rheumatoid arthritis, which is expected to boost the usage of autoinjectors and pen injectors during the forecast period. Thus, the growing prevalence of diabetes and other chronic diseases would fuel the market demand over the next few years. The introduction of advanced devices with Wi-Fi and Bluetooth connectivity facilitating effective management of patient health records is also expected to boost the product demand.
The application of prefilled injectors is currently limited to emergency rooms in hospitals and for the treatment of certain chronic diseases. These injection devices are considered ideal containers for vaccines and other biotech drugs, which otherwise tend to become unstable and react with the material of the container resulting in altered drug potency. Rising preference for biotechnology drugs and the emerging biotech sector presenting greater opportunities are expected to have a positive impact on market development during the forecast period.
To request a sample copy or view summary of this report, click the link below: www.grandviewresearch.com/industry-analysis/pre-filled-syringes-market
Further key findings from the study suggest:
Currently, the use of glass prefilled syringes is greater than plastic syringes owing to high demand from healthcare professionals. Glass prefilled syringes are easy to use and lower the risks at the time of injection
However, the plastic syringes are rapidly replacing glass syringes due to the advent of advanced, biocompatible materials, such as Polypropylene (PP) and crystal clear polymer
Europe was the dominant regional market for prefilled syringes in 2015. High adoption of patient safety measures and the presence of key companies are the factors responsible for its the region’s growth
On the other hand, North America is expected to witness the fastest growth rate during the forecast period due to rapid adoption of prefilled syringes in this region
Major companies in the global market are Gerresheimer AG, Haselmeier AG, Nipro Medical Corporation, Unilife Corporation, Owen Mumford Ltd., Schott Group, Datwyler Pharma Packaging, and Becton, Dickinson and Company
The market for prefilled syringe manufacturing is consolidated; however, new companies are bringing innovative technologies to this field, which can be used for the manufacturing of auto-injectors.
Grand View Research has segmented the global prefilled syringes market on the basis of type, material, application, distribution channel, and region:
Prefilled Syringes Type Outlook (Revenue, USD Million, 2014 - 2025)
Disposable
Reusable
Prefilled Syringes Material Outlook (Revenue, USD Million, 2014 - 2025)
Glass
Plastic
Prefilled Syringes Application Outlook (Revenue, USD Million, 2014 - 2025)
Anaphylaxis
Rheumatoid Arthritis
Diabetes
Others
Vaccines and Other Biotech Drugs
Prefilled Syringes Distribution Channel Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals
Mail Order Pharmacies
Ambulatory Surgery Centers
Prefilled Syringes Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
Europe
Asia Pacific
Latin America
MEA
The U.S.
Canada
The U.K.
Germany
Japan
India
Brazil
Mexico
South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
0 notes
Text
Prefilled Syringes Market
Market Overview
Global "Prefilled Syringes Market" is expected to grow at a CAGR of 10.3% during the forecast period (2021-2028)
Prefilled syringes are readily available syringes with drug components to be administered. Prefilled syringes are being used to deliver drug categories such as vaccines, therapeutic proteins, blood stimulants, erythroproteins, and more.
The key issues related to parenteral drug delivery such as lack of convenience, affordability, lack of accuracy in drug volume, sterility, safety, etc. are overcome by prefilled syringes. Prefilled syringes edge on traditional parental drugs over contamination issues. Thus, these are used across the vast array of therapeutic sector
Download Free Samples @ https://www.datamintelligence.com/download-sample/pre-filled-syringes-market
Market Drivers and Restraints
The global Prefilled syringe market is propelled by multiple factors such as technological advancements, the high prevalence of chronic diseases and disorders, and the growing adoption of self-injection devices.
One of the primary reasons for the rapid growth of prefilled syringe technology is its suitability for home use, a prevalent healthcare trend that provides the benefit of convenience for regular patients. Pen injectors and auto-injectors are common for self-administered insulin injections and other hormone replacement therapies which are also used in the home-based treatment of major therapeutic areas like autoimmune disease, cancer, and allergies.
Moreover, the reduction in the amount of active pharmaceutical ingredient (API) used by Prefilled syringes would reduce the cost of Prefilled syringe manufacturing and will help the manufacturers to achieve sustainable growth in the production of Prefilled syringes products.
Product recalls, high manufacturing costs, limited manufacturing facilities are such factors that are expected to hinder the market over the forecast period.
Further, the surge in Biosimilars in the pharmaceuticals market and increasing availability of injectable drugs in Prefilled form would provide a lucrative opportunity to the market.
Market Segmentation
The global Prefilled syringe market is segmented by material type, by design, and by application.
The material type segment is classified into Glass-based and Plastic-based Prefilled syringes.
By design, the market is segmented into single-chamber prefilled needles, dual-chamber prefilled syringes, and customized prefilled syringes.
Further, by application, the global Prefilled syringe market is categorized into anaphylaxis, rheumatoid arthritis, diabetes, and others.
The majority of the prefilled syringes are made out of glass. However, the adoption of plastic-based cyclopoly olefin (COP) resin is driving the growth of the plastic-based Prefilled syringe market over the forecast period.
This resin is becoming more common due to the material’s improved break resistance, as well as its decreased surface reactivity and drug absorption rates compared to glass. Japan is one of the leading countries in the plastic-based Prefilled syringes market. The state has more than 50% of the Prefilled syringes in plastic form.
Geographical Analysis
The global Prefilled syringe market is segmented as North America, Europe, Asia-Pacific, South America, and Rest of the World. Europe dominated the prefilled syringe market in 2017, and it is expected to grow in the forecast period.
High adoption of patient safety measures and the presence of critical companies are the factors responsible for the growth of Europe Prefilled Syringe Market. However, North America is expected to witness the fastest growth in the regional market owing to the rapid adoption of Prefilled syringes for multiple drugs in 2017.
View Full Report @ https://www.datamintelligence.com/research-report/pre-filled-syringes-market
Competitive Trends
Major players in the prefilled syringes market are focused on expanding their product range with technologically advanced products. This, in turn, will help the companies to increase their supply and marketing capacity to sustain the market pressure.
In July 2015, Vetter launched Vetter-Ject, a closure system that is suitable for the filling of highly sensitive drug components. Likewise, in April 2015, SCHOTT introduced a new polymer prefillable syringe design—SCHOTT TopPac. The plan is aimed at refining the safety and stability of sensitive drugs.
The new product launch is the key strategy adopted by the market leaders to improve their market presence and grab a significant share of the market.
For instance, Novartis, in September 2018, received FDA approval for their Xolair (omalizumab) prefilled syringe. The Prefilled syringe drug is approved for allergic asthma and chronic idiopathic urticaria indications. Similarly, W. L. Gore & Associates, Inc. (“Gore) plans to commercially launch the GORE ImproJect Plunger for Prefilled Syringes by 2018
For Enquiry @ https://www.datamintelligence.com/enquiry/pre-filled-syringes-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
0 notes
Text
Connected Drug Delivery Devices Market: Current Analysis and Forecast (2021-2027)
Connected drug delivery devices are mainly developed for the supervision and counseling of patients in a home setting. These devices offer various advantages such as adherence trackers, dose reminders, and monitoring of various diseases such as asthma, clinically isolated syndrome, Chronic Obstructive Pulmonary Disease (COPD), diabetes, and hypertension. Moreover, the sensors incorporated in the delivery devices help to monitor the side effects and evaluation of the effect of change in dose. The adherence trackers help to check whether the patients are taking the required dose at right time or not, whereas the apps associated with the connected delivery devices help to record the effect of treatment, safety of dose, and tolerability. Flexi-Q eMU-P electromechanical multi-use auto-injector system consists of a single-use cassette, reusable device, and a pre-filled syringe. This device is mainly used for various diseases which require a repeated dose of injections, such as autoimmune diseases, multiple sclerosis, blood-related disorders, and growth hormone deficiencies. The main advantage of Flexi-Q eMU-P is that it is reusable and easily affordable. The demand for Connected drug delivery devices is increasing on account of increasing penetration of the Internet of Things (IoT) in the healthcare devices, increasing focus on patient compliance, quality of healthcare, rising awareness of costs, increasing use of self-administered drugs, rising healthcare programs, and initiatives to spread the connected drug delivery devices' awareness. For example, Propeller Health company has conducted around 60 connected medical programs to spread awareness of connected drug delivery devices. The company provides add-on devices for inhalers that are synchronized with the patient's software for the analysis of symptoms and diseases.
Insights Presented in the Report
"Amongst Products, Connected sensors segment holds the major share."
Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/connected-drug-delivery-devices-marketcurrent-forecast-market-2021-2027-860
Based on Products, the global Connected drug delivery devices market is fragmented into Connected Sensors and Integrated Connected Devices. The connected sensors segment is expected to dominate the market owing to its easy integration inside the already existing delivery devices without any interruption in their normal functioning.
"Amongst Connected Sensors, Connected Inhaler Sensors is anticipated to grow at the highest CAGR during the analyzed period."
Connected Sensors are further bifurcated into Connected Inhaler Sensors and Connectable Injection Sensors. The demand for connected inhaler sensors is on rise on account of the high prevalence of respiratory diseases. Several research companies are working to control the incidence of respiratory diseases, for instance, propeller health is providing digital health solutions for respiratory medicine with the combination of analytics, inhaler device sensors, and mobile applications. Propeller Health has launched several connected inhaler device sensors such as metered-dose inhalers (MDIs), dry powder inhaler (DPI), and soft mist inhaler (SMI) for the monitoring of COPD and Asthma.
Amongst Integrated Connected Devices, the Connected Inhaler Devices segment holds the major share"
The integrated connected devices are expected to register the fastest CAGR in the upcoming period. The integrated connected devices segment is also sub-divided into Connected Inhaler Devices and Connected Injection Devices. Connected Inhaler Devices hold several benefits over the Connected Injection Devices because of the needleless delivery of the drug. The demand for inhalational devices in the market is increasing owing to the high prevalence of chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD), and asthma. As per Burden of Obstructive Lung Disease (BOLD), the global prevalence of COPD is 10.1% in 2019.
Amongst Technology, the Bluetooth segment holds the major share"
Based on Technology, the market is fragmented into Bluetooth, Near-field communication (NFC), and Other Technologies. Bluetooth sub-segment is expected to show significant growth in the forecast period owing to its high use in drug delivery devices, and its low-cost connectivity access to smartphones. The Bluetooth technology is easily available in comparison to NFC and other technologies. For example, Teva a pioneer in enhancing health and improving access to quality healthcare for society has launched a Bluetooth-enabled albuterol sulfate rescue inhaler. The new inhaler is available by prescription to U.S. patients age 4 and older, according to the Tel Aviv, Israel-based company. ?ProAir Digihaler' connects with the smartphone to detect and record COPD and Asthma symptoms.
Amongst End-User, the Homecare segment holds the major share"
Based on End-user, the market is divided into Healthcare Providers, Homecare, Hospitals, and Others. The home care segment is expected to register the fastest CAGR from 2021-2027 because of the rise in product acceptance. The advantage of using these products in the homecare setting is easy administration and without the need for healthcare practitioners. Furthermore, the increasing incidents of chronic diseases such as diabetes, Chronic Obstructive Pulmonary Disease (COPD), and Cardiovascular Diseases (CVDs) are expected to fuel the homecare segment growth in the forecast period. For instance, as per WHO, Cardiovascular diseases (CVDs) are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Four out of 5CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age.
"North America is the largest markets and Europe is expected to be the fastest-growing markets"
For a better understanding of the market adoption of the Connected Drug Delivery Devices, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World.
Competitive Scenario
Some of the major players operating in the market include Propeller Health (Reciprocal Labs Corporation), Proteus Digital Health, BIOCORP, Merck KGaA, Adherium Limited, West Pharmaceutical Services, Inc., Aterica Digital Health, Phillips Medisize, Teva Pharmaceutical Industries Ltd and FindAir . Several M&As along with partnerships have been undertaken by these players to boost their presence in different regions
Reasons to buy this report:
? The study includes market sizing and forecasting analysis validated by authenticated key industry experts
? The report presents a quick review of overall industry performance at one glance
? The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
? Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
? The study comprehensively covers the market across different segments
? Deep dive regional level analysis of the industry
Customization Options:
Connected Drug Delivery Devices Market can further be customized as per the requirement or any other market segment.
Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/connected-drug-delivery-devices-marketcurrent-forecast-market-2021-2027-860
Table of content
1 MARKET INTRODUCTION 1.1 Market Definitions 1.2 Limitation 1.3 Stake Holders 1.4 Currency Used in Report 2 RESEARCH METHODOLOGY OR ASSUMPTION 2.1 Research Process of the Connected Drug Delivery Devices Market 2.2 Research Methodology of the Connected Drug Delivery Devices Market 2.3 Forecasting Method 2.4 Respondent profile 2.5 Main Objective of the Connected Drug Delivery Devices Market Study 3 MARKET SYNOPSIS 4 EXECUTIVE SUMMARY 5 GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET ANALYSIS 2019-27F 6 MARKET INSIGHTS BY PRODUCTS 6.1 Integrated Connected Devices 6.1.1 Connected Inhaler Devices 6.1.2 Connectable Injection Devices 6.2 Connected Sensors 6.2.1 Connected Inhaler Sensors 6.2.2 Connected Injection Sensors 7 MARKET INSIGHTS BY TECHNOLOGY 7.1 Bluetooth 7.2 Near-field communication (NFC) 7.3 Other Technologies 8 MARKET INSIGHTS BY END-USER 8.1 Healthcare Providers 8.2 Homecare 8.3 Hospitals 8.4 Other end-users 9 MARKET INSIGHTS BY REGION 9.1 NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET 9.1.1 United States 9.1.2 Canada 9.1.3 Rest of North America 9.2 EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET 9.2.1 Germany 9.2.2 France 9.2.3 United Kingdom 9.2.4 Italy 9.2.5 Spain 9.2.6 Rest of Europe 9.3 ASIA PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET 9.3.1 China 9.3.2 Japan 9.3.3 India 9.3.4 Australia 9.3.5 Rest of Asia Pacific 9.4 REST OF WORLD CONNECTED DRUG DELIVE
CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
0 notes
Text
Epinephrine Market To Surpass US$ 5.2 Billion By 2026 - Coherent Market Insights
Global Epinephrine Market, by Product Type (Auto-injector, Prefilled Syringes, and Ampoules and Vials), by Application (Anaphylaxis, Cardiac Arrest, Superficial Bleeding, Respiratory Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,040 million in 2017, and is projected to exhibit a CAGR of 11.0% over the forecast period (2018 – 2026), as highlighted in a new report published by.
Significant number of novel pipeline products to augment the market growth the manufacturers are focused on developing and commercializing innovative drugs and novel drug delivery systems of therapeutic molecules to improve patient quality of life and to cater the clinical shortcomings of the commercially available products. According to the Mayo Clinic, 2016, more than 200,000 cases of anaphylaxis occur annually in the U.S., indicating the higher number of potential patient pool in the region. Also, the World Allergy Organization, in 2015 estimated that up to two percent of the global population, accounting for 150 million people are expected to experience anaphylaxis during their lifetime. In July 2018, INSYS Therapeutics, Inc. demonstrated the results of early clinical trial for its investigational epinephrine nasal spray, as a potential needle-free, non-invasive, and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. The investigators also highlighted the benefits of effective needleless alternative delivery options showing rapid drug absorption. In August 2018, FDA granted Fast Track designation for the epinephrine nasal spray. Furthermore, in April 2018, Aquestive Therapeutics initiated the Phase-1 clinical trials for its complex molecule programs- AQST-108 epinephrine molecule for anaphylaxis, which is administered via sublingual route.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2401
Browse 36 Market Data Tables and 34 Figures spread through 175 Pages and in-depth TOC on “Epinephrine Market”- Global Forecast to 2026, by Product Type (Auto-injector, Prefilled Syringes, and Ampoules and Vials), by Application (Anaphylaxis, Cardiac Arrest, Superficial Bleeding, Respiratory Disorders and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
The market players are focused on strengthening strategic collaborations to provide products freely at retail outlets, considering shortages in supply of competitors' epinephrine auto-injectors. For instance, in September 2018, Walgreens and Kaleo entered into partnership under which AUVI-Q would be available at all pharmacies across the U.S. This step will aid in increasing accessibility of epinephrine auto-injector. Also, in July 2018, Adamis Pharmaceuticals announced that Sandoz, a Novartis division, bought the rights to market its epinephrine device, a pre-filled 0.3 mg-dose syringe called Symjepi in the U.S. market. In 2015, Impax Laboratories, Inc. acquired Tower Holdings, Inc. including subsidiaries Amedra Pharmaceuticals LLC. Amedra is manufacturer of the Adrenaclick (epinephrine injection) auto-injector.
Browse Research Report: https://www.coherentmarketinsights.com/market-insight/epinephrine-market-2401
Key Takeaways of the Epinephrine Market:
The global epinephrine market is expected to exhibit a CAGR of 11.0% over the forecast period, owing to the approval of cost-effective generic auto-injectors in the market, and strategic support of companies and government agencies for increasing generic epinephrine adoption.
Among product type, auto-injector segment held a dominant position in the epinephrine market in 2018, owing to the wide use of the product in auto-injectable form due to ease of administration and rapid onset of action.
Among application, anaphylaxis segment held a dominant position in the epinephrine market in 2018, owing to high incidence rate of anaphylaxis due to consumption of food products such as peanut or tree nut in children and increasing supplemental new drug application in infants.
Companies operating in the global epinephrine market include Mylan N.V., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Impax Laboratories, Inc., Kaleo, Inc., Adamis Pharmaceuticals Corporation, Bausch Health Companies, ALK- Abello A/S
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2401
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
0 notes
Link
The medications are delivered using injectable route of administration. This route is convenient and offers greater bioavailability as compared to oral route of administration. There are technological advancements in devices used for injection of medicines. These modifications allow patients to take the medications daily using injectable route of administration. The new products such as auto-injectors, pre-filled syringes, pen-injectors, etc. are proving to be ground breaking technologies in this segment. These advancements are boosting the growth rate of the market over the conventional injectables.
0 notes
Text
By 2026, Injectable Drug Delivery Market To Surpass US$ 32.5 - Coherent Market Insights
From 2018 – 2026, The global injectable drug delivery market is expected to exhibit a CAGR of 8.3%
Request for Sample PDF Copy:
https://www.coherentmarketinsights.com/insight/request-pdf/2768
Description:
Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site, which enhances the patient’s compliance to the drug. The Injectable delivery enhances the rapid absorption of drug from various sites such as subcutaneous, intravenous, and intramuscular. The injectable delivery increases the bioavailability of the drug at the systemic circulation, which offers availability of drug at intended site of action.
The global injectable drug delivery market size was valued at US$ 15,939.0 million in 2017, and is expected to exhibit a CAGR of 8.3% over the forecast period (2018 – 2026).
Figure 1. Global Injectable Drug Delivery Market Value (US$ Mn), by Region, 2017
Injectable Drug Delivery | Coherent Market Insights
Increasing prevalence of chronic diseases such as diabetes and anaphylaxis is expected to propel growth of the global injectable drug delivery market
Increasing prevalence of chronic diseases such as diabetes and other diseases is expected to drive the market growth. According to the World Health Organization (WHO), in November 2011, around 60 million people in Europe suffered from diabetes, of which around 10.3% were men and 9.6% were women aged 25 years and above. Similarly, according to World Health Organization (WHO) 2018 factsheet, around 8.5% adults aged 18 years and above had diabetes in 2014 globally.
Moreover, the market players are focused on product development and launch of injectors, which is expected to propel growth of the global injectable drug delivery market over the forecast period. For instance, in 2016, Berlin-Chemie launched BerliPen areo 3 in Germany. BerliPen areo 3 is a 300 unit insulin pen, which can be used with six different insulins in the treatment of type 1 and 2 diabetes. Similarly, in August 2018, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for generic version of Mylan’s EpiPen and EpiPen Jr. Teva Pharmaceuticals is the first generic manufacturer that received the FDA approval.
However, increasing product recalls is expected to hinder the market growth. In December 2012, Bracco Diagnostics Inc., initiated a Class I recall of nine lots of Isovue Pre-Filled Power Injector Syringes, which are to be used with Stellant CT Injection Systems, due to presence of visible particles in syringes observed at the end of standard stability studies on retained samples, according to the U.S. Food and Drug Administration (FDA)
Figure 2. Global Injectable Drug Delivery Market Share (%), by Usability,2018 and 20 Injectable Drug Delivery | Coherent Market Insights
Source: Coherent Market Insights Analysis (2019)
Increasing product approval and launch in North America is expected to bolster the market growth
North America holds dominant position in the global injectable drug delivery market, owing to increased focus of regional players in research and development and product launches. In 2017, Bayer received U.S. Food and Drug Administration (FDA) approval for a connected auto-injector-BETACONNECT for relapsing-remitting multiple sclerosis medication and companion app- myBETAapp. The app allows patients to automatically have a record of all their injections and share that record with their nurse or physician. Similarly, in October 2018, Genentech announced the U.S. Food and Drug Administration (FDA) approval for single-dose prefilled syringes (PFS) for Xolair (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications.
Moreover, increasing incidence of chronic diseases such as anaphylaxis, diabetes, and cardiac arrest in the region is expected to support growth of the market during the forecast period. For instance, according to Journal of Allergy and Clinical Immunology, 2014, prevalence of anaphylaxis in the U.S. was 1.6% in the general population, while the number of hospitalizations associated with the disease is ever increasing in the U.S.
Furthermore, increasing initiatives by companies to make auto-injectors available to patients suffering from anaphylaxis is expected to boost global injectable drug delivery market. For instance, Mylan N.V. provides discount cards to epinephrine buyers, and offers discounts up to US$ 300 on branded version of EpiPen and up to US$ 25 on the approved generic version of EpiPen.
Key Players
Major players operating in the global injectable drug delivery market include Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, and Injex Pharma GmbH
About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.
Buy Report Here:
https://www.coherentmarketinsights.com/insight/buy-now/2768
Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
0 notes
Text
Prefilled Syringes Market Projected to Augment Forecast Period until 2025
Prefilled Syringes- Insights into Novel Drug Delivery System
The prefilled syringes are one of the fastest growing choices for the unit dose delivery and has emerged as one of the most convenient way of drug delivery method in the recent years. The extensive use of prefilled syringes has enabled the pharmaceutical companies to minimize drug-wastage and increase the life-span of the product at the same time.
The plastic disposable syringes has created a revolution in the healthcare market which has been enhanced by the introduction of sterile prefilled syringes that enables safe self-administration of injectable drugs to patients sitting at home without a need to visit hospitals. According to National Center for Biotechnology Information (NCBI), 25% of expenditure on drugs goes unused and wasted in the United States while 3-7% of medications intended towards patients goes unused.
Request A Sample Copy: http://bit.ly/2yr8acp
These massive revenues could be directed in a useful way with the use of prefilled syringes in the market that enables to improve the shelf life of the drugs as well as avoids wastage of drugs as the syringes are filled with exact volume and concentration of the drug that will deliver optimum results. Prefilled syringes make a profitable deal for the pharmaceutical companies too, as these companies can be benefitted from the less over-fill of drugs as compared to the vials that serves to be an important advantage, particularly in case of costly biopharmaceuticals.
The global prefilled syringes market was valued at US$ 2,805.4 million in 2015 and is expected to witness a CAGR of 11% during the forecast period (2017 – 2025).
Rise in prevalence of chronic diseases globally augments the market growth of the prefilled syringes
Chronic diseases such as type 1 diabetes is encountered among a significant population across the globe, wherein the patients are suggested to undergo regular intra-venous administration of insulin to control their sugar levels inability in natural insulin production. These injections are easy and feasible task with the use of pre-filled syringes that makes the self-administration more convenient and viable.
Furthermore, the drug interaction with the packaging material leading to chemical reaction that may change the effectivity and impact of the drug on the patient marks as one of the serious issue restraining the market growth as these chemicals can prove fatal at certain point of times. However, key players operating the prefilled syringes market are engaged in research activities to come up with packaging material that will not interfere in the composition of the drug dosage.
Key players indulged in strategic implementation of various policies for the stabilization of prefilled syringes as well as to encounter other issues associated with it
In 2015,Gerresheimer and Corning Inc. signed a joint venture in order to accelerate the innovations for pharmaceutical glass packaging materials. The companies entered into a 10 year supply agreement for borosilicate glass tubes focusing on packaging of pharmaceutical products.
In 2016, BESPAK launched SYRINA AR 2.25 auto injector that enables fully-automatic delivery of viscous drug formulations. The innovative auto-injector is specifically tailored to inject higher viscosities enabling safe use of glass syringes.
Click To Read More On: Prefilled Syringes Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]
0 notes
Text
Auto Injectors Market to Witness a Pronounce Growth during 2018-2027
Auto-injector devices are defined as the new injectable, with a user-centric design approach that automatically injects a needle and performs the surgical procedures in order to increase self-injectable devices and reduce dependence on healthcare professionals. These are specialized instruments that can be used to avoid needle stick injury and reduce needle phobia among patients. These are the revolutionary instruments which are invented to ensure complete dosage with painless drug delivery. Factors such as rising prevalence of anaphylaxis, rheumatoid arthritis and multiple sclerosis is anticipate to increasethe consumption of auto-injectors over the forecast period. Factors like growing advancement in the drug delivery technology, growing patient preferences for Auto-injectorsin emergency care and increasing number of key participantsmanufacturing generic versions are anticipated to enhance the growth of global Auto-injectorsmarket over the forecast period.
Get Sample Copy Of The Report@ https://www.trendsmarketresearch.com/report/sample/3310
Sale of Auto-injectorsis relativelyhealthy in the U.S. market in the recent years, making North America the most lucrative region globally.North America Auto-injectorsmarketis estimated to value at US$ XX.XMn in 2016, with the U.S. accounting for majority of revenue share. By product, PrefilledAuto-injectorsaccounted for higher revenue share in global Auto-injectorsmarketas compared to other product segments..
By Indication type, anaphylaxis indication type segment accounted for highest revenue share and is expected to reflect CAGR the forecast period. The growing preference for injectable drug delivery is expected to fuel the market for sterile drugs globally. Self-administration of drugs through usage of pre-filled syringes is one such instance where patients can save on large caregiver fees. There is an increased demand for large molecule drugs in pre-filled syringes as compared to small molecule drugs in pre-filled syringes.
By Distribution Channel, Online Pharmacies segmentaccount for higher demand for Auto-injectorsas compared to other end user segments such as Drug Stores, Hospital Pharmacies and Retail Pharmacies segment.PrefilledAuto-injectorscherishsupportable demand for Online Pharmacies owing to the fact that Epipen Auto Injector which is used in anaphylaxis is made mandatory at several public places along with the first aid.
Report For Sample with TOC@ https://www.trendsmarketresearch.com/report/requesttoc/3310
Moreover certain change in prices made by Mylan N.V. by launching a generic version of Epipen is expected to drastically affect the sales revenue of auto-injectors market in the near future. The prices are dropped down to nearly half of the initial prices that will affect the sales revenue but will eventually support to build a strong volume base for auto-injectors market.
Key players in the global Auto-injectors market include Becton, Dickinson and Company, Sanofi, Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc. and Eli Lilly and Company and others. Major market players are implementing different strategies and are focusing on product development through research. Many players have are yet to launch the auto injectors in the market and are soon expected to launch.
Report Analysis@ https://www.trendsmarketresearch.com/report/auto-injectors-market
Contact Us:
One Vincent Square Westminster, London SW1P 2PN United Kingdom Phone: +442033221521 Email: [email protected] Website: https://www.trendsmarketresearch.com
0 notes
Text
Auto Injectors Market Key Development the COVID-19
Auto-injector devices are defined as the new injectable, with a user-centric design approach that automatically injects a needle and performs the surgical procedures in order to increase self-injectable devices and reduce dependence on healthcare professionals. These are specialized instruments that can be used to avoid needle stick injury and reduce needle phobia among patients. These are the revolutionary instruments which are invented to ensure complete dosage with painless drug delivery. Factors such as rising prevalence of anaphylaxis, rheumatoid arthritis and multiple sclerosis is anticipate to increasethe consumption of auto-injectors over the forecast period. Factors like growing advancement in the drug delivery technology, growing patient preferences for Auto-injectorsin emergency care and increasing number of key participantsmanufacturing generic versions are anticipated to enhance the growth of global Auto-injectors market over the forecast period.
Sale of Auto-injectorsis relativelyhealthy in the U.S. market in the recent years, making North America the most lucrative region globally.North America Auto-injectorsmarketis estimated to value at US$ XX.XMn in 2016, with the U.S. accounting for majority of revenue share. By product, PrefilledAuto-injectorsaccounted for higher revenue share in global Auto-injectorsmarketas compared to other product segments..
Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/3310
By Indication type, anaphylaxis indication type segment accounted for highest revenue share and is expected to reflect CAGR the forecast period. The growing preference for injectable drug delivery is expected to fuel the market for sterile drugs globally. Self-administration of drugs through usage of pre-filled syringes is one such instance where patients can save on large caregiver fees. There is an increased demand for large molecule drugs in pre-filled syringes as compared to small molecule drugs in pre-filled syringes.
By Distribution Channel, Online Pharmacies segmentaccount for higher demand for Auto-injectorsas compared to other end user segments such as Drug Stores, Hospital Pharmacies and Retail Pharmacies segment.PrefilledAuto-injectorscherishsupportable demand for Online Pharmacies owing to the fact that Epipen Auto Injector which is used in anaphylaxis is made mandatory at several public places along with the first aid.
Moreover certain change in prices made by Mylan N.V. by launching a generic version of Epipen is expected to drastically affect the sales revenue of auto-injectors market in the near future. The prices are dropped down to nearly half of the initial prices that will affect the sales revenue but will eventually support to build a strong volume base for auto-injectors market.
Key players in the global Auto-injectors market include Becton, Dickinson and Company, Sanofi, Pfizer, Inc., Mylan N.V., Novartis AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc. and Eli Lilly and Company and others. Major market players are implementing different strategies and are focusing on product development through research. Many players have are yet to launch the auto injectors in the market and are soon expected to launch.
More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/3310
0 notes
Text
Asia Pacific (APAC) Drug Delivery Devices Market - Trends and Forecast to 2024
Asia Pacific Drug Delivery Devices Market, By Route of Administration (Oral (Solid, Liquid, Semi-Solid), Injectable, Topical, Pulmonary (MDI, DPI, Nebulizers), Nasal, Ocular, Implantable, Transmucosal), By End-User (Hospitals, Ambulatory Surgery Centers/Clinics, Home Care Settings, Diagnostic Centers, Others), By Country (China, India, Japan, South Korea, Singapore, Australia, Rest of APAC) – Industry Trends and Forecast to 2024
APAC Drug Delivery Devices Market is expected to reach USD 235.8 billion by 2024 from USD 130.9 billion in 2016, at a CAGR of 7.6% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Drug delivery is a process of introducing a therapeutic effect in the human body by administering a pharmaceutical drug at a specific targeted site. Drug delivery system improves the efficacy and safety of drug by controlling the rate, time and release of drug in the body. The drug delivery market is segmented on the basis of route of administration, end users, and region.
Request-a-sample@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=asia-pacific-apac-drug-delivery-devices-market
· On the basis of route of administration the APAC drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal. Oral drug is further segmented based on form into solid drug, semi-solid drug and liquid drug.
· The solid drugs include and are categorized as tablets, capsules, powders and pills. The semi-solid drugs are further segmented into gels, emulsions and elixirs. The liquid drugs are further classified into solutions and syrups.
· The Injectable drug delivery segment is further segmented into devices and formulations. The devices segment is categorized as conventional injections, self Injectable devices, Needle free injectors, auto injectors, pen injectors, wearable injectors, other devices. The convention injections sub-segment is further classified by material into glass and plastic injections, by usability disposable and reusable injections and, by type into fillable and pre-filled syringes.
· The Injectable drug delivery formulations are categorized as conventional drug delivery, novel drug delivery, long acting Injectable. Based on the route of administration, oral drug delivery market dominates the market in 2015 and in the near future injectable drug delivery market will dominate the APAC drug delivery devices market with the largest share in the drug delivery market. Topical drug delivery market is considered to be the fastest growing market with the CAGR of 11.5%.
Speak-to-analyst@https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=asia-pacific-apac-drug-delivery-devices-market
The pulmonary drug delivery segment is further classified into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers. The nebulizers are further sub segmented into jet nebulizers, ultrasonic nebulizers and soft mist nebulizers.
Ocular drug delivery devices are segmented into liquid ocular drugs, semi solid ocular drugs and ocular devices. Liquid ocular drug delivery includes eye drops and liquid sprays. Semi solid ocular drug delivery includes gels and ointments. The ocular device includes drug coated lenses and ocular inserts.
Nasal drug delivery devices are segmented into nasal drops, powders, gels, and sprays. The topical drug delivery segment is segmented based on form into liquid, semi-solid, solid and transdermal. The transdermal topical drug delivery device includes transdermal patches and transdermal gels. The implantable drug delivery devices segment includes active and passive implantable drug delivery devices. The transmucosal drug delivery segment is sub segmented into oral transmucosal and others. The oral transmucosal segment includes products such as buccal and sunlingual drug delivery devices, while the others segment includes rectal transmucosal drug delivery and vaginal transmucosal drug delivery.
On the basis of end users the APAC drug delivery devices market is segmented into hospitals, over the counter, ambulatory surgery centers/clinics, home care settings, diagnostic centers, and others. The hospitals segment dominate the North America drug delivery devices market.
The major factors contributing to the growth of the APAC drug delivery devices market are rising prevalence of chronic diseases, growing geriatric population, increase in diagnosis, growth of biosimilars, new product launches, drug innovation, technological advancements, and decrease in the level of pain. On the other hand, factors such as side effects and injuries, infections, safety measures regarding the use of devices used for the administration of drug, patent expiry, product recall and patent cliff hampers the growth of the market.
Compotator
The major players covered in the report are Alcoa Corporation, Endurance Technologies Limited, Ryobi Limited, DyCast Specialties Corporation, Consolidated Metco, Inc., Alcast Technologies, Ningbo Beilun Create Mould Machine Co., Ltd, Leggett & Platt, Incorporated, Martinrea Honsel Germany GmbH, Gibbs, Dynacast, Reliance Foundry Co. Ltd., Toyota Industries Corporation, LA Aluminum, TPi Arcade, Drahtwerk Elisental W. Erdmann GmbH & Co., Wagstaff Inc., Ningbo Innovaw Mechanical CO.,LTD., Modern Aluminum Castings CO., INC. and Pacific Die Casting Corp.
Request for Toc@https://www.databridgemarketresearch.com/toc/?dbmr=asia-pacific-apac-drug-delivery-devices-market
Global Asia Pacific (APAC) Drug Delivery Devices Market Size, Status and Forecast 2018 – 2025
1 Market Overview
2 Manufacturers Profiles
3 Global APAC Cancer Diagnostics Sales, Revenue, Market Share and Competition by Manufacturer
4 Global APAC Cancer Diagnostics Market Analysis by Regions
5 North America Global APAC Cancer Diagnostics by Countries
6 Europe Global Asia Pacific (APAC) Drug Delivery Devices by Countries
7 Asia-Pacific Asia Pacific (APAC) Drug Delivery Devices by Countries
8 South America Global Asia Pacific (APAC) Drug Delivery Devices Diagnostics by Countries
9 Middle East and Africa Global Asia Pacific (APAC) Drug Delivery Devices Diagnostics by Countries
10 APAC Cancer Diagnostics Market Segment by Type
11 Global Asia Pacific (APAC) Drug Delivery Devices Market Segment by Application
12 Global APAC Cancer Diagnostics Market Forecast
13 Sales Channel, Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendixes
Based on geography the market is segmented into 7 countries, China, India, Japan, South Korea, Singapore, Australia and rest of APAC. Japan is expected to dominate the market, while China and India are expected to be the growing with highest CAGR in the forecast period.
The report also includes company share analysis for the major companies operating in this market by countries. The details of mergers & acquisitions, product launches, expansions, and product life cycle matrix is also a part of this report. Some of the players in the market Bayer AG, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc. , Merck & Co., Sanofi, Antares Pharma, and 3M.
Buynow@https://www.databridgemarketresearch.com/checkout/buy/enterprise/asia-pacific-apac-drug-delivery-devices-market
Reasons to Purchase this Report
· The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
· Regions/Countries that are expected to witness the fastest growth rates during the forecast period
· The latest developments, market shares, and strategies that are employed by the major market players
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
· Amyotrophic Lateral Sclerosis (ALS) Market
· Antifungal Drugs Market
· Cutaneous Lupus Erythematosus Market
0 notes
Text
HW1Case Q3
Facts of the case:
In 2007, the EpiPen cost $94. Between 2007 and 2009 the price of the EpiPen grew by only $6, increasing the total cost to $100. That price is reasonable, or at least far more reasonable than what would happen in the years to come. Mylan Pharmaceuticals has adjusted the price of their life saving device a lot, but essentially it has gone from $50.00 per autoinjector to $600.00 for a two-pack. The drastic change contributed to Mylan increasing their profits by over a billion dollars per year. It is good news for the board members of Mylan, but bad news for everyone who depends on the EpiPen in the event of an emergency.
Other companies over the years have tried to bring a less expensive alternative to the market, but each time they were blocked. Mylan holds a monopoly over the emergency epinephrine market, primarily because of their patent over their auto-injector. When companies would attempt to produce a generic alternative the FDA would block them. In one example a company attempted to sell syringes that were pre-filled with Epinephrine.
It would appear that Mylan Pharmaceuticals is obeying all of the laws and regulations that a pharmaceutical company has to follow, and in addition to that our Patent laws is protecting Mylan from having a competitor copy their designs of the auto-injector.
Just because something is legal, does that make it right?
Analysis:
In my opinion, no matter how you look at it, Mylan Pharmaceuticals committed an unethical act when they increased the price of their drug. When it comes to applying different ethical standards to this situation, a few interesting points come up.
For example, under Deontological ethics if one follows the rules they are considered to be acting ethically. As I mentioned previously, Mylan Pharmaceuticals is not breaking any laws by doing what they are doing, and the regulatory agencies seem to also side with Mylan. In any other context, a company putting profits first would not seem as bad to me. However, in this case there are people who might literally die if they cannot afford this product. For that reason, I think you have to consider deontological ethics on a deeper level when it comes to this case. God, or your preferred religious figure, would not take too kindly to Mylan’s business decision as it is considered a sin to place greed above the well-being of others.
When it comes to virtue ethics and utilitarianism, the answer is even more clear. What Mylan decided to do was disgusting and completely unethical. I had to state this is such terms to stress the difference between deontological ethics where there was at least some argument to be made. No one with good character would decide to increase the price of their life saving drug just because they have a monopoly on the market and can afford to force their customers who have no other option but to pay the absurd price. As for utilitarianism, it is cut and dry that the people who made the decision were putting money over the well-being of the many.
My Conclusions:
I believe the reason this story bothers me so much is because it is clear why this occurred. With no competition, Mylan did not have to worry about losing customers. They exploited that circumstance to force said customers to either pay their new price, or go without. On one hand it is a shrewd business decision that netted over a billion dollars per year, but it came at the cost of being unethical.
I suppose when I think of the medical field, even pharmaceuticals, the idea of helping or healing people comes to mind. The type of decision Mylan did is something I would expect a retail store to do if they had a monopoly on a particular item or something. I would not think that someone who wanted to save lives would adjust their prices to such an extreme degree, just because they could.
Future Environment:
This case is important because we are talking about a situation in-which people who needed a life saving drug were subjugated into being at the mercy of a monopoly. As technology develops and continues to become advanced, who knows what new life saving inventions or ideas could come into play. I can only hope that whoever creates them will be more ethical than Mylan Pharmaceuticals. Imagine a cure for a disease, or a terminal illness being hidden behind a massive paywall...just because whoever made it was able to patent a simple aspect of it. Mylan doesn’t have a monopoly on Epinephrine, only the injector for it. Such a simple thing was exploited today, I hate to imagine what potential pitfalls we may see in the future.
Future Scenario:
It is hard to predict the future, but in this case I have a couple of ideas. The one thing we know to expect about the future is automation. Eventually automation should be able to take over practically any job that humans currently do. When that comes, I predict we will cease to be preoccupied solely by profits. I mean when people no longer need to or are able to work, what comes after that?
For the record, I am not a socialist but I find it hard to argue that at some point our economy will have to adjust to our future conditions. I’m not saying that socialism is the answer either, maybe it will be something entirely new. I’m definitely not for the government having more power and I doubt that will change.
My point in all of this is that I hope we will be able to become more ethical as a society, especially for circumstances like health and medicine. I’m sincerely hoping that once we no longer need to worry about advertisements and profits then maybe things will be accessible for all of those who need it. We just need the technological advancements to make it all possible. I suppose that is the difference between the future I envision and the future someone like Bernie Sanders might envision. The end goals are somewhat similar, but the means and timing of it all is completely different. (Not trying to get political, I just think this idea is applicable. I have nothing against Bernie Sanders, I just think our political landscape is a little too clumsy and unreliable these days. I would prefer to have some sort of A.I. created first to assist. I feel as if I am going off topic now.)
In a future where you don’t have to worry about profits and advertisements, things like patents might not be as important as they are now. Though I hate to imagine how horrible the flow of information would become then. I suppose for literary work and other forms of art, the patent laws should remain.
0 notes
Text
Prefilled Syringes Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026
As per the recent study by FutureWise on prefilled syringes, the global market is predicted to value over US$ 10 Bn by the end of the assessment year 2026. Prefilled syringes are utilised to package a variety of medications and drugs, such as vaccines, therapeutic proteins and insulin. In recent years, prefilled syringes have gained colossal demand as it is affordable, accurate, convenient and safe. Healthcare specialists benefit from precise, pre-measured dosages, elimination of medication and dosage errors, and reduced risk of microbial contamination.
Despite holding multiple benefits, factors such as high manufacturing cost of prefilled syringes, storage difficulties, and stringent norms set by government authorities may hinder the growth of the market. Nonetheless, manufacturers should focus on technological improvements and innovations, and catering to the unmet demand for specific syringes as these are the key market growth aspects.
Increase in Prevalence of Chronic Diseases Globally to Augment the Growth of Prefilled Auto Syringes Market
Owing to the rising incidences of chronic diseases globally, healthcare professionals are exploring seeking alternate methods for patient care. As per the Centres for Disease Control and Prevention in 2014, approximately 29.1 million people in the United States were suffering from diabetes, which is 9.3% of the total population. Patients suffering from Type 1 diabetes are advised to undergo periodic intravenous administration of insulin to control their sugar levels inefficiency in natural insulin production. Prefilled syringes assist in self-administration of these drugs by making the treatment affordable, feasible and precise. Due to the rising incidents of chronic diseases in North America, the market displays notable growth.
APEJ region is poised to exhibit growing inclination towards injectable drug delivery systems. The growing ageing population in countries such as India and China, and increasing initiatives in the pharmaceutical industry, is surging the demand for prefilled syringes to treat diabetes and other autoimmune diseases.
Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=11&page=requestsample
Further Significant Highlights:
Glass prefilled syringes are forecasted to account for the largest market share. The growth of this segment can be associated with the soaring use of glass in manufacturing syringes due to its resistance towards chemical and heat, and nonreactive nature.
Single-chamber prefilled syringes are poised to dominate the market owing to the growing adoption of self-administered parenteral drugs
The market for prefilled syringe manufacturing is concentrated; nevertheless, innovative technologies in packaging material contributed by new players can be adapted to manufacture auto-injectors
Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=94&page=askfordiscount
Vital Questions Answered
How rapidly will the prefilled syringes market grow globally?
What are the key factors influencing or restraining the growth of the market?
Key regions to focus on?
Investigating several aspects of the market with the help of Porter’s five forces analysis
Recognising the latest advancements, market shares, and strategies applied by the significant market players
Table of Contents
1. Introduction
1.1. Scope and Objective
1.2. Assumptions and Acronyms
1.3. Forecast Factors
1.4. Research Methodology
2. Executive Summary
2.1. Industry Cluster Analysis
2.2. Competition Matrix
2.3. Strategies Recommendations
3. Market Definition
3.1. Report Scope (Inclusions & Exclusions)
3.2. Market Segmentation
4. Global Pre-Filled Syringes Market Overview
4.1. Global Pre-Filled Syringes Market Revenue (USD Mn)
5. Key Inclusions
5.1. Porter’s Five Force analysis
5.2. Market Dynamics
5.3. Industry Trends
5.4. Regulatory Guidelines
5.5. Opportunities in Pre-Filled Syringes
6. Competition Dynamics
6.1. Company Share Analysis (2018)
6.2. Top 10 Product Pricing by Region
7. Global Pre-Filled Syringes Market Revenue (USD Mn), 2018-2026 by Product Type
7.1. Key Market Findings
7.2. Long Term ROI Segments
7.3. Revenue Opportunity Influencing Factors
7.4. Market Revenue (USD Mn) Assessment and Forecast by Product Type, 2018-2026
7.4.1 Single Chamber Pre-filled Syringe
7.4.2 Dual Chamber Pre-filled Syringe
8. Global Pre-Filled Syringes Market Revenue (USD Mn), 2018-2026 by Material
8.1. Key Market Findings
8.2. Long Term ROI Segments
8.3. Revenue Opportunity Influencing Factors
8.4. Market Revenue (USD Mn) Assessment and Forecast by Product Type, 2018-2026
8.4.1 Glass
8.4.2 Plastic
9. Global Pre-Filled Syringes Market Revenue (USD Mn), 2018-2026 by End User
9.1. Key Market Findings
9.2. Long Term ROI Segments
9.3. Revenue Opportunity Influencing Factors
9.4. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
9.4.1 Retail Pharmacies
9.4.2 Institutional Distribution
9.4.3 Online Pharmacies
10. Global Pre-Filled Syringes Market Revenue (USD Mn), 2018-2026 by Region
10.1.Key Market Findings
10.2.Long Term ROI Segments
10.3.Revenue Opportunity Influencing Factors
10.4.Market Revenue (USD Mn) Assessment and Forecast by Region,2026
10.4.1 North America
10.4.2 Latin America
10.4.3 Europe
10.4.4 Asia Pacific
10.4.5 Rest of world
11. North America Pre-Filled Syringes Market Revenue (US$ Mn), 2018-2026
11.1. Key Market Findings
11.2. Long Term ROI Segments
11.3. Revenue Opportunity Influencing Factors
11.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
11.4.1 US
11.4.2 Canada
11.5. Market Revenue (USD Mn) Assessment and Forecast by Product Type, 2018-2026
11.5.3 Single Chamber Pre-filled Syringe
11.5.4 Dual Chamber Pre-filled Syringe
11.6. Market Revenue (USD Mn) Assessment and Forecast by Material, 2018-2026
11.6.5 Glass
11.6.6 Plastic
11.7. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
11.7.7 Retail Pharmacies
11.7.8 Institutional Distribution
11.7.9 Online Pharmacies
12. Latin America Pre-Filled Syringes Market Revenue (US$ Mn), 2018-2026
12.1. Key Market Findings
12.2. Long Term ROI Segments
12.3. Revenue Opportunity Influencing Factors
12.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
12.4.1 Brazil
12.4.2 Mexico
12.4.3 Argentina
12.4.4 Rest of Latin America
12.5. Market Revenue (USD Mn) Assessment and Forecast by Product Type, 2018-2026
12.5.5 Single Chamber Pre-filled Syringe
12.5.6 Dual Chamber Pre-filled Syringe
12.6. Market Revenue (USD Mn) Assessment and Forecast by Material, 2018-2026
12.6.7 Glass
12.6.8 Plastic
12.7. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
12.7.9 Retail Pharmacies
12.7.10 Institutional Distribution
12.7.11Online Pharmacies
13. Europe America Pre-Filled Syringes Market Revenue (US$ Mn), 2018-2026
13.1. Key Market Findings
13.2. Long Term ROI Segments
13.3. Revenue Opportunity Influencing Factors
13.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
13.4.1 Germany
13.4.2 France
13.4.3 Spain
13.4.4 UK
13.4.5 Russia
13.4.6 Poland
13.4.7 Rest of Europe
13.5. Market Revenue (USD Mn) Assessment and Forecast by Product Type, 2018-2026
13.5.8 Single Chamber Pre-filled Syringe
13.5.9 Dual Chamber Pre-filled Syringe
13.6. Market Revenue (USD Mn) Assessment and Forecast by Material, 2018-2026
13.6.10 Glass
13.6.11 Plastic
13.7. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
13.7.12 Retail Pharmacies
13.7.13 Institutional Distribution
13.7.14 Online Pharmacies
14. Asia Pacific America Pre-Filled Syringes Market Revenue (US$ Mn), 2018-2026
14.1. Key Market Findings
14.2. Long Term ROI Segments
14.3. Revenue Opportunity Influencing Factors
14.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
14.4.1 Emerging Asia
14.4.1.1 China
14.4.1.2 India
14.4.1.3 ASEAN-5
14.4.1.4 Rest of Emerging Asia
14.4.2 Japan
14.5. Market Revenue (USD Mn) Assessment and Forecast by Product Type, 2018-2026
14.5.3 Single Chamber Pre-filled Syringe
14.5.4 Dual Chamber Pre-filled Syringe
14.6. Market Revenue (USD Mn) Assessment and Forecast by Material, 2018-2026
14.6.5 Glass
14.6.6 Plastic
14.7. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
14.7.7 Retail Pharmacies
14.7.8 Institutional Distribution
14.7.9 Online Pharmacies
15. Rest of World America Pre-Filled Syringes Market Revenue (US$ Mn), 2018-2026
15.1. Key Market Findings
15.2. Long Term ROI Segments
15.3. Revenue Opportunity Influencing Factors
15.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026
15.4.1 Middle East
15.4.2 South Africa
15.4.3 North Africa
15.4.4 Rest of World
15.5. Market Revenue (USD Mn) Assessment and Forecast by Product Type, 2018-2026
15.5.5 Single Chamber Pre-filled Syringe
15.5.6 Dual Chamber Pre-filled Syringe
15.6. Market Revenue (USD Mn) Assessment and Forecast by Material, 2018-2026
15.6.7 Glass
15.6.8 Plastic
15.7. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026
15.7.9 Retail Pharmacies
15.7.10 Institutional Distribution
15.7.11 Online Pharmacies
16. Company Profiles
16.1. Competition Landscape
16.2. Global Company Share (USD Mn) Overview, 2018
16.3. Company Profiles
16.3.1 Mylan N.V.
16.3.1.1 Corporate Overview
16.3.1.2 Financial Performance
16.3.1.3 Peer Comparison & 3C marketing equation
16.3.1.4 Company Strategy & Channel Management
16.3.2 Amedra Pharmaceuticals LLC
16.3.2.1 Corporate Overview
16.3.2.2 Financial Performance
16.3.2.3 Peer Comparison & 3C marketing equation
16.3.2.4 Company Strategy & Channel Management
16.3.3 Owen Mumford
16.3.3.1 Corporate Overview
16.3.3.2 Financial Performance
16.3.3.3 Peer Comparison & 3C marketing equation
16.3.3.4 Company Strategy & Channel Management
16.3.4 Ypsomed AG
16.3.4.1 Corporate Overview
16.3.4.2 Financial Performance
16.3.4.3 Peer Comparison & 3C marketing equation
16.3.4.4 Company Strategy & Channel Management
16.3.5 Antares Pharma
16.3.5.1 Corporate Overview
16.3.5.2 Financial Performance
16.3.5.3 Peer Comparison & 3C marketing equation
16.3.5.4 Company Strategy & Channel Management
16.3.6 SHL Group
16.3.6.1 Corporate Overview
16.3.6.2 Financial Performance
16.3.6.3 Peer Comparison & 3C marketing equation
16.3.6.4 Company Strategy & Channel Management
16.3.7 Johnson & Johnson
16.3.7.1 Corporate Overview
16.3.7.2 Financial Performance
16.3.7.3 Peer Comparison & 3C marketing equation
17. Research Sources & Primary Verbatim
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.
Contact Us:
Company Name: FutureWise Research Contact Person: Vinay Thaploo Email: [email protected] Phone: +44 141 628 9353 / +1 970 279 4295 City: Leeds Country: United Kingdom Website: www.futurewiseresearch.com
#Prefilled Syringes Market Share#Prefilled Syringes Market Size#Prefilled Syringes Market Trend#Prefilled Syringes Market Forecast#Prefilled Syringes Market
0 notes
Text
Novartis to promote epinephrine shot in U.S. pharmacies amid EpiPen scarcity
http://tinyurl.com/y4mnywrc (Reuters) – Novartis AG (NOVN.S) mentioned on Tuesday it will make its generic pre-filled epinephrine photographs instantly out there in native pharmacies throughout the US, as a scarcity of Mylan NV’s (MYL.O) EpiPen emergency allergy therapy drags on resulting from manufacturing issues. FILE PHOTO: EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical firm to be used by extreme allergy victims are seen in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photograph Novartis’ Sandoz unit launched the Symjepi epinephrine photographs to be used in hospitals in January and had mentioned it will make the therapy out there in pharmacies in a phased method. The Swiss drugmaker has an unique settlement with Adamis Prescription drugs Corp (ADMP.O) to distribute and commercialize Symjepi in the US. Novartis mentioned each the grownup and pediatric doses of Symjepi can be instantly out there in native U.S. pharmacies. The wholesale worth for a two-pack of adult-dose syringes is $250, Novartis mentioned, beneath the $300 charged by Mylan for its licensed generic and for Teva’s (TEVA.TA) generic model of the EpiPen auto-injector. Mylan nonetheless dominates the marketplace for emergency allergy photographs with its EpiPen that delivers a dose of epinephrine within the occasion of extreme, doubtlessly life-threatening allergic reactions to quite a few triggers, resembling bee stings or peanuts. However there was a scarcity of EpiPens in the US, Europe and Canada resulting from manufacturing delays. The U.S. Meals and Drug Administration added the therapy to its checklist of medication in scarcity greater than a yr in the past, and it stays on that checklist. Pfizer Inc’s (PFE.N) Meridian Medical unit, which produces all EpiPens bought globally at a single plant close to St. Louis, has been hit by a collection of producing issues. The corporate mentioned in a press release on Tuesday that it anticipates additional provide shortages over the approaching months. There’s historically excessive demand for the gadgets in the summertime as households look to resume prescriptions forward of sending kids to summer time camp or the brand new faculty yr. Teva has constructed important market share with its generic this yr, reaching 18% of the market in late June, in response to a analysis observe from Leerink that cited IQVIA (IQV.N) prescription quantity information. Teva mentioned in Might it anticipated to achieve round 20% market share by the top of the second quarter and will method 50% market share by the top of the yr. Reporting by Aakash Jagadeesh Babu and Tamara Mathias in Bengaluru and Michael Erman in New York; Enhancing by Maju Samuel and Invoice Berkrot Our Requirements:The Thomson Reuters Trust Principles. Source link
0 notes
Text
Pre-filled Syringes Market to Witness Widespread Expansion by 2024
Syringe filled with fixed dosage of therapeutic drug is known as prefilled syringe. The devices are used for delivering drugs with efficient efficacy, accuracy, safety, convenience, sterility, affordability and accessibility. The above features make pre-filled syringes more advantageous than traditional methods of drug delivery. Moreover, prefilled syringe decrease contamination and possible dosing errors.
The technological advancements in the pre-filled syringes, increasing prevalence of chronic diseases, and large population base are the major factors driving the growth of the pre-filled syringes market. Furthermore, the key players are establishing production facilities in both developed and emerging markets which will further boost the growth of the market. However, the growth of the prefilled syringes is hindered with low awareness among consumers and few product recalls.
Request for a sample of report @
https://mindaspiremarketresearch.com/request-sample/report/cha-market-analysis
The pre-filled syringes market is witnessing development of technologically advanced pre-filled syringes and growing usage of self-injection devices as major trends. For instance, in July 2015, Vetter introduced Vetter-Ject, a new closure system for its prefilled syringes. This syringe system is suitable for filling of highly sensitive drug molecules. Similarly, earlier, in April, 2015, SCHOTT lauched a new polymer pre-filled syringe design—SCHOTT TopPac. The design was aimed at improving the safety and stability of the sensitive drug molecules. Moreover, many pharmaceutical companies are focusing on bringing in advancements in self administration therapies. In this direction, in August, 2016, Mylan N.V., through its U.S. subsidiary, launched the first generic EpiPen Auto-Injector . Similarly, in July 2016, Bristol-Myers Squibb commercially introduced the ORENCIA ClickJect Auto injector.
The Global Prefilled Syringes Market was valued at $3.7 billion in 2017, and is estimated to reach $7.6 billion by 2024, registering a CAGR of 9.7% from 2018 to 2024.
Global Pre-filled Syringes Market: Segmentation
By Material
Glass-based
Plastic-based
By Design
Single-chamber Prefilled Syringes
Dual-chamber Prefilled Syringes
Customized Prefilled Syringes
By Application
Anaphylaxis
Rheumatoid Arthritis
Diabetes
Others (Cancer, Multiple Sclerosis, and others)
Geographically, the global prefilled syringes market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2017, Europe commanded a major share of the prefilled syringes market. However, Asia-Pacific is expected to witness the highest growth rate during the forecast period. Growth in the Asia-Pacific market can be attributed to the increasing demand for self-administered treatments and high penetration of self-injection devices, growing aging population, and increasing prevalence of diabetes.
Ask an Analyst @
https://mindaspiremarketresearch.com/inquire/report/cha-market-analysis
Becton, Dickinson and Company (U.S.), Gerresheimer AG (Germany), SCHOTT AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Ompi (Italy), Catalent, Inc. (U.S.), Weigao Group (China), Vetter Pharma International GmbH (Germany), Nipro Corporation (Japan), and MedPro Inc. (U.S.) are some of the key players in the prefilled syringes market.
0 notes